http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-043847-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46 |
| filingDate | 2004-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-043847-A1 |
| titleOfInvention | DERIVATIVES OF 3-AZABICICLO [3.2.1.] OCTANO |
| abstract | This refers to 3-azabicyclo [3.2.1] octane derivatives, pharmaceutical compositions comprising derivatives of this type and methods for using derivatives of that type to treat disease states, disorders and conditions mediated by opioid receptors. This also refers in particular to the use of derivatives of this type to treat certain disorders and conditions, for example irritable bowel syndrome, drug addiction, depression, anxiety, schizophrenia and eating disorders among others. Claim 1: A compound according to formula (1), or a pharmaceutically acceptable salt thereof: wherein Ra is H or a group - (CH2) n-CR1R2R4-; the AR cycle is an aryl or heteroaryl group; X is H, halogen, -OH, -CN, C ::: C-R3a, a C1-4 alkyl group optionally substituted with one to three halogen atoms, or a -O (C1-4 alkyl) group optionally substituted with 1 to 3 halogen atoms; Q is H, halogen, a C1-6 alkyl, -OH, -CN, -OCH3, -NH2, -NH (C1-4 alkyl), -N (C1-4 alkyl) (C1-4 alkyl), -C (= O) NH2, -C (= O) NH (C1-4 alkyl), - C (= O) N (C1-4 alkyl) (C1-4 alkyl), -NHC (= O) R15, -NHS (= O) 2R15, a 5- to 7-membered carbocyclic or heterocyclic group, or forms a carbocyclic or heterocyclic group fused to phenyl or fused to 5 to 7 membered heteroaryl with an adjacent atom in the phenyl or heteroaryl group to which it is attached , said carbocyclic or heterocyclic group condensed with phenyl or condensed with heteroaryl optionally at least one unsaturated bond, said heterocyclic group or heterocyclic group condensed with phenyl or condensed with heteroaryl optionally containing at least one heteroatom selected from N, O, and S , said carbocyclic or heterocyclic group or said carbocyclic or heterocyclic group being fused to phenyl or fused to heteroaryl optionally substituted with at least one substituent which is choose from H, halogen, -OH, = O, -C ::: C-R3a, C1-6 alkyl, -O (C1-6 alkyl), C3-6 cycloalkyl or - (CH2) n-aryl, in the that said C1-6 alkyl, -O (C1-6 alkyl) or C3-6 cycloalkyl groups may optionally be substituted by one or more halogen atoms and said aryl portion of said - (CH2) n-aryl is optionally substituted by one or more substituents that are selected from H, halogen, C1-4 alkyl, and -O (C1-4 alkyl), said C1-4 alkyl and -O (C1-4 alkyl) groups being optionally substituted by one or more Atoms of halogen, groups -N (R4a) (R5a), -N (R4b) S (O) mR6a, -N (R4c) C (O) R7a or -N (R4d) C (O) OR7b; R3a, R4a, R4b, R4c, R4d and R5a are independently H or C1-6 alkyl which may be optionally substituted with one or more halogen groups, or R4a and R5a, together with the N atom to which they are attached, form a group 4 to 7-membered heterocycle that may not be substituted or substituted with one or more substituents that are selected from C1-4 alkyl, -O (C1-4 alkyl), -OH, = O, -NR16aR16b, halogen or -C ::: C-R3a; R6a is a C1-6 alkyl, an aryl group or a heteroaryl in which said alkyl, aryl or heteroaryl group is not substituted or substituted with one or more substituents that are selected from halogen, C1-4 alkyl, -OH, - O (C1-4 alkyl), - (C1-4 alkyl) -O- (C1-4 alkyl) or - (CH2) n-NR21R22; R7a and R7b are independently selected from C1-6 alkyl, C3-6 cycloalkyl, and aryl (wherein each of said C1-6 alkyl, C3-6 cycloalkyl, and aryl may independently be unsubstituted or substituted with halogen substituents or C1-4 alkyl), or R7a is H; R1 and R2 are independently H, a C1-6 alkyl, - (CH2) j-aryl, - (CH2) j-heteroaryl, wherein said alkyl group, - (CH2) j-aryl or - (CH2) j- heteroaryl is optionally substituted with one or more R16 groups, or with the C to which R1 and R2 are attached, R1 and R2 form a C3-7 carbocyclic group or a 4- to 7-membered heterocyclic group, wherein said heterocyclic group comprises from one to three heteroatoms that are selected from the group consisting of O, S and N and said carbocyclic or heterocyclic group optionally contains a group -C (= O) or optionally contains one or more double bonds and is optionally condensed or substituted with a C6-14 aryl group or a 5-14 membered heteroaryl, wherein said C3-7 heterocyclic 4 to 7 membered carbocyclic group consisting of R1 and R2 may be optionally substituted with one to three R16 groups, and said aryl group or optionally condensed or substituted heteroaryl can each independently be optionally substituted with one to six R16 groups; each R16 is independently selected from R17, H, halogen, -OR17, -NO2, -CN, C1-6 alkyl, C3-6 cycloalkyl, -C (R4) R16aR16b, aryl optionally substituted with 1 to 3 R4 groups, - ( CH2) vNR17R18, -NR17C (= O) R18, -C (= O) NR17R18, -OC (= O) R17, -C (= O) OR17, -C (= O) R17, -NR17C (= O) OR18, -NR17C (= O) NR18R19, -NR17S (= O) 2R18, -NR17S (= O) 2NR18R19 and -S (= O) 2R17; R3 is H, F, Cl, -OH, C1-4 alkyl, -C ::: N, -NR17C (= O) R18, -C (= O) NR17R18, -O (C1-4 alkyl), - ( CH2) nOH, - (CH2) nC ::: N, - (CH2) n-NR17C (= O) R18, - (CH2) nC (= O) NR17R18, - (CH2) nO (C1-4 alkyl) or - (CH2) n-NR16aR16b; R4 is absent or is H, C1-4 alkyl, which optionally contains one or two unsaturated bonds, -OH, -O (C1-4 alkyl), - (C1-4 alkyl) OH, - (CH2) n-NR16aR16b, - (CH2) n-NHC (= O) (C1-4 alkyl), - (CH2) n-NO2, - (CH2) nC ::: N, - (CH2) nC (= O) NH2, - (CH2 ) nC (= O) NR16aR16b; R5 and R8 are independently selected and H, Cl, F, -OH, C1-4 alkyl, -O (C1-4 alkyl, -C (= O) R20, - (C1-4 alkyl) -OR20, -C ( = O) OR20, -OC (= O) R20, -S (O) mR20 and -NHSO2 (C1-4 alkyl); R6, R7, R9, R10, R11, R12, R13, and R14 are each independently selected of H, F, Cl, -OH, -C1-4 alkyl and -O (C1-4 alkyl); R15, R17, R18 and R19 are independently H, -C1-4 alkyl, - (C2-4 alkyl) - O- (C1-4 alkyl), - (CH2) v-NR21R22 or a 4- to 7-membered heterocyclic group optionally substituted with a C1-4 alkyl; each R16a and R16b is independently selected from H and C1-4 alkyl; or independently in each case of -C (R4) R16aR16b, R16a and R16b are connected to form a C3-7 carbocyclic ring; R20 is a C1-4 alkyl group, a C3-7 carbocyclic group or a 4-7 membered heterocyclic group comprising one to three heteroatoms that are selected from the group consisting of O, S and N, in which said carbocyclic and heterocyclic groups are optionally substituted independently with one to three R16 groups, which optionally independently contain one or more double bonds, and are optionally fused to a C6-14 aryl group or a C5-14 heteroaryl group comprising one to three heteroatoms that are selected from the group consisting in O, S and N and wherein said optionally fused aryl or heteroaryl groups may each be optionally independently substituted with one to six R16 groups; R21 and R22 are each independently H or C1-6 alkyl; or independently in each case of -NR21R22, R21 and R22 are connected to form a 4- to 7-membered heterocyclic ring comprising from one to three heteroatoms that are selected from O, S and N; j is in each case independently an integer from 0 to 5; m is in each case independently an integer from 0 to 2; n is each case independently an integer from 0 to 5; v is in each case independently an integer from 0 to 5; or a pharmaceutically acceptable salt thereof; with the conditions that a) when Ra is a - (CH2) nCR1R2R4 and n is 0, and when the C to which R1, R2 and R4 are attached has hybridization is sp3 (ie, "saturated"), then none of R1 , R2 and R4 may be a heteroatom or contain a heteroatom that is directly linked to the C of said group - (CH2) nCR1R2R4; b) R15 cannot be H when it is part of a group -NHS (= O) 2R15, R17 cannot be H when it is part of a group -S (= O) 2R17 and R18 cannot be H when it is part of a group group -NR17S (= O) 2R18; c) when R3 is OCH3 or OH, the AR ring and its substituents cannot be 3-hydroxyphenyl or 3-methoxyphenyl; d) when the AR ring is a phenyl group, then Q and X are not both H; e) when - (CH2) v is connected to N, O or S, then v cannot be 1; and f) the AR ring and its substituents cannot be 4- (6-aminopyridin-2-yl) phenyl. |
| priorityDate | 2003-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.